文献速递胸部肿瘤放疗

非小细胞肺癌术后放疗患者中更高的肺部与心脏剂量分别降低早期与长期生存

Higher Lung and Heart Doses Decrease Early and Long-Term Survival, Respectively, in Patients With Non-Small Cell Lung Cancer Undergoing Postoperative Radiation.
PubMed 文献 · Adv Radiat Oncol · 2023-03-10

该回顾性分析纳入307例接受术后放疗的非小细胞肺癌患者,总剂量50 Gy,以36个月为界标分别分析早期与长期生存。心脏剂量与长期生存显著相关(HR 1.14,P=.015),肺部剂量与早期生存边缘显著相关(HR 1.03,P=.07),24与48个月敏感性分析结果一致。

要点

  • 心脏剂量与长期生存显著相关(HR 1.14,P=.015)。
  • 肺部剂量与早期生存边缘显著相关(HR 1.03,P=.07)。
  • 24与48个月界标分析结果与36个月一致。

核心结论

  • 在接受术后放疗的非小细胞肺癌患者中,较高的心脏剂量与长期生存下降相关,较高的肺部剂量与早期生存下降相关。

研究设计与样本

  • 回顾性分析纳入307例接受术后放疗的非小细胞肺癌患者,总剂量50 Gy,以36个月为界标分别计算早期与长期生存的风险比,并采用稳定逆概率治疗加权平衡高剂量组与低剂量组特征。
  • 在24个月与48个月进行敏感性分析。

主要发现

  • 中位随访67.42个月。
  • 心脏剂量与长期生存显著相关(HR 1.14,P=.015),与早期生存(HR 0.97,P=.41)及全程生存(HR 1.02,P=.58)无显著相关。
  • 肺部剂量与早期生存边缘显著相关(HR 1.03,P=.07),与长期生存(HR 1.00,P=.85)及全程生存(HR 1.02,P=.12)无显著相关。
  • 在稳定逆概率治疗加权前后,较高的心脏剂量和肺部剂量分别与长期生存和早期生存下降相关。
  • 24个月与48个月界标分析显示一致结果。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Cardiopulmonary toxic effects may reduce the efficacy of postoperative radiation therapy (PORT) in patients with non-small cell lung cancer (NSCLC). However, few studies have examined whether the heart and lung doses affect overall survival (OS). We investigated the correlation of heart and lung doses with OS in patients with NSCLC undergoing PORT. METHODS AND MATERIALS: This retrospective analysis included 307 patients with NSCLC undergoing PORT. The total dose was 50 Gy. Landmark analyses were performed at 36 months, with hazard ratios (HRs) calculated separately for events occurring up to 36 months (early survival) and after 36 months (long-term survival). Stabilized inverse probability of treatment weighting (sIPTW) was performed to balance the characteristics of the high- and low-dose groups. We performed sensitivity analyses at 24 and 48 months. RESULTS: The median follow-up period was 67.42 months. Heart doses were significantly correlated with long-term survival (HR, 1.14; P = .015) but not with early survival (HR, 0.97; P = .41) or whole survival (HR, 1.02; P = .58). Lung doses were marginally significantly correlated with early survival (HR, 1.03; P = .07) but not with long-term survival (HR, 1.00; P = .85) or whole survival (HR, 1.02; P = .12). Higher heart and lung doses were associated with decreased long-term and early survival, respectively, before and after sIPTW. Landmark analyses at 24 and 48 months showed consistent results. CONCLUSIONS: For patients with NSCLC undergoing PORT, a higher heart dose was associated with decreased long-term survival, whereas a higher lung dose was associated with decreased early survival.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Ma Z, Liu Y, Bao Y, et al. Higher Lung and Heart Doses Decrease Early and Long-Term Survival, Respectively, in Patients With Non-Small Cell Lung Cancer Undergoing Postoperative Radiation. Adv Radiat Oncol. 2023. PMID: 37152488. doi:10.1016/j.adro.2023.101213

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。